LGI1 and autoimmune encephalitis: Among the nine basket trials addressing non-oncological RDs, the average number of centers was notably lower, at 24, with the study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO study) involving the largest number of sites at 81.